EDITORIALS J Am Soc Nephrol 14: 2411–2413, 2003

Complement Regulatory : Are They Important in Disease?

MASAOMI NANGAKU Division of Nephrology and Endocrinology, University of Tokyo School of Medicine, Tokyo, Japan.

In this issue of JASN, Turnberg et al. (1) report that the in the CD59 expressed a severe PNH-like phe- manifestations of disease in an -mediated notype (12,13). Given that his is the only known case of glomerulonephritis model are exacerbated in Cd59a knockout selective CD59 deficiency, however, the evidence supporting a mice. Exacerbation was associated with an increase in C9 critical role of CD59 in vivo remains flimsy. deposition in glomeruli, suggesting that the deficiency of Using a neutralizing antibody, Matsuo and colleagues Cd59a allowed greater C5b-9 deposition, which in turn led to (14,15) performed various studies to elucidate the biologic role more severe renal disease. of CD59 in the kidney in rodents. Neutralization of renal CD59 These findings are potentially of great importance. Comple- function alone did not induce complement-mediated injury in ment activation plays a critical role in tissue injury, including healthy rats. However, any interpretation of experiments in rats various forms of glomerulonephritis (2,3) and tubulointerstitial and mice is confounded by the presence of Crry, a rodent- injury (4,5). Against this, the host is endowed with rigorous specific analog of DAF and membrane cofactor (MCP) regulatory mechanisms (6). The balance between acceleration that inhibits early complement activation; therefore, these data and inhibition of complement activation is critical to whether do not necessarily exclude a crucial role of complement acti- complement activation leads to host defense or tissue injury of vation regulation at the C5b-9 formation level. host organs. It therefore comes as no surprise that functional In contrast, the suppression of CD59 significantly enhanced abnormality or deficiency of complement regulatory proteins complement activation and exacerbated tissue injury in animals in humans results in disorders characterized by excessive com- given a neutralizing antibody against a complement regulatory plement activation. protein at the C3/C5 convertase level (16). Neutralization of In humans and animals, genetic abnormalities of , a CD59 has been shown to exacerbate disease manifestations in soluble complement regulatory protein, induce membranopro- two different models of immune-mediated glomerular endo- liferative glomerulonephritis or hemolytic uremic syndrome thelial injury in rats (17,18). Passive Heymann nephritis, a (7,8). Deficiency of CD59, an important regulator of comple- model of membranous nephropathy in rats, is mediated by ment activation, which serves as the one and only membrane- C5b-9 formation on , which is induced by adminis- bound inhibitor of C5b-9 formation, also results in a well- tration of heterologous anti-Fx1A antibodies. Fx1A is a crude known hematologic disease, paroxysmal nocturnal fraction of rat proximal tubule brush-border , and hemoglobinuria (PNH). Deficiency of CD59 in combination Quigg and colleagues (19) showed that antibodies neutralizing with a lack of decay accelerating factor (DAF), a membrane- complement regulatory proteins including CD59 in the rat bound complement inhibitor at the C3/C5 convertase step, on glomerulus are required to induce complement activation and erythrocytes is the cause of complement-mediated hemolysis in proteinuria. All these studies suggest that CD59 is essential patients with PNH. when the upstream inhibitors of the complement cascade are Is CD59 the most relevant complement regulatory protein to overwhelmed by either excessive activation or loss of inhibi- the pathogenesis of PNH? An isolated deficiency of DAF has tory function. been described in four human families that had an unusual The study by Turnberg et al. (1) confirms and extends group termed Inab (9,10). Despite the total previous studies, demonstrating a protective role of Cd59a in absence of DAF on all circulating cells, none of the propositi immune renal injury utilizing genetically engineered mice. had symptoms suggestive of PNH (11). In contrast, a man who Mouse molecular genetics have enabled quite sophisticated had a global deficiency of CD59 due to a single nucleotide study of the biologic role of various molecules, including complement components and complement regulatory proteins (20). Two groups, including ours, recently demonstrated exac- Correspondence to DR. Masaomi Nangaku, Division of Nephrology and Endo- erbation of the anti–glomerular basement membrane nephritis crinology, University of Tokyo School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. Phone: 81-3-5800-8648; Fax: 81-3-5800-8806; E-mail: model by independent targeting of the DAF gene (21,22). [email protected] Quigg and colleagues (23–25) also showed that overexpression 1046-6673/1409-2411 of soluble Crry in transgenic mice protects the kidney against Journal of the American Society of Nephrology immune injury. Copyright © 2003 by the American Society of Nephrology Cd59a knockout mice are phenotypically normal and do not DOI: 10.1097/01.ASN.0000088010.15313.A1 develop spontaneous , despite the increased 2412 Journal of the American Society of Nephrology J Am Soc Nephrol 14: 2411–2413, 2003 sensitivity of their erythrocytes to induced complement lysis inappropriate complement activation also retards progression of (26,27). In the Turnberg et al. study (1), however, deficiency of chronic proteinuric renal disease (36,37). This field holds exciting Cd59a led to an increase in complement activation in associ- promise and should lead to the development of novel therapeutic ation with more severe manifestations of nephrotoxic serum approaches not only in immunologic kidney disease but possibly nephritis. This finding establishes a critical role of Cd59a in also in chronic non-immunologic renal injury. autoimmune kidney injury in vivo. Is CD59 important only in immunologic disease? Acosta et References al. (28) recently showed that CD59 is inhibited by glycation, 1. Turnberg D, Botto M, Warren J, Morgan BP, Walport MJ, Cook the non-enzymatic attachment of glucose to amino acids in HT CD59a deficiency exacerbates accelerated nephrotoxic ne- proteins, which occurs in diabetes mellitus as a consequence of phritis in mice. J Am Soc Nephrol 14: 2271–2279, 2003 hyperglycemia. Malfunction of CD59 may be important in the 2. Couser WG: Pathogenesis of glomerular damage in glomerulo- pathogenesis of non-immunologic tissue injury such as diabetic nephritis. Nephrol Dial Transplant 13[Suppl 1]: 10–15, 1998 complications, including atherosclerosis and nephropathy. 3. Couser WG: Pathogenesis of glomerulonephritis. Kidney Int Several questions remain. Two groups have independently 42[Suppl]: S19–26, 1993 developed Cd59a knockout mice. The Cd59a-deficient mice 4. Nangaku M: Final common pathways of progression of renal established by Morgan’s group, which was employed in this diseases. Clin Exp Nephrol 6: 182–189, 2002 study, show spontaneous intravascular hemolysis (27). In con- 5. Nangaku M: Mechanisms of tubulointerstitial injury in the kid- trast, Song’s gene-targeted animals show none of these signs, ney. Intern Med 2003, in press 6. Nangaku M: Complement regulatory proteins in glomerulone- including differences in reticulocyte count or changes in phritis. Kidney Int 54, 1419–1428, 1998 plasma and urine hemoglobin level (26). Cd59b is expressed 7. Pickering MC, Cook HT, Warren J, Bygrave AE, Moss J, Wal- predominantly in the testes, and this is the rationale why port MJ, Botto M: Uncontrolled C3 activation causes membrano- Turnberg and colleagues used Cd59a knockout mice to study proliferative glomerulonephritis in mice deficient in complement the functional role of CD59 in the kidney. However, mice with factor H. Nat Genet 31, 424–428, 2002 a targeted deletion of the Cd59b gene develop severe hemolytic 8. Manuelian T, Hellwage J, Meri S, Caprioli J, Noris M, Heinen S, anemia in addition to male infertility (29). It is likely that the Jozsi M, Neumann HPH, Remuzzi G, Zipfel PF: Mutations in relative roles of the different complement regulatory proteins, factor H reduce binding affinity of and heparin and surface such as Cd59a, Cd59b, and DAF, in protecting self cells from attachment to endothelial cells in hemolytic uremic syndrome. complement attack vary depending on the tissue or site of J Clin Invest 111: 1181–1190, 2003 complement attack as well as on the mechanism and degree of 9. Lin RC, Herman J, Henry L, Daniels GL: A family showing inheritance of the Inab phenotype. Transfusion 28: 427–429, activation. 1988 Why are studies on complement regulatory proteins of in- 10. Telen MJ, Green AM: The Inab phenotype: Characterization of terest to clinical nephrologists? Recent progress in molecular the membrane protein and complement regulatory defect. Blood biologic techniques has made feasible a variety of new ap- 74: 437–441, 1989 proaches utilizing recombinant complement inhibitors. The 11. Reid ME, Mallinson G, Sim RB, Poole J, Pausch V, Merry AH, first application of reagents produced by molecular techniques Liew YW, ReTanner MJ: Biochemical studies on red blood cells to the treatment of renal disease arising from perturbed com- from a patient with the Inab phenotype (decay-accelerating factor plement activation in vivo was reported by Couser et al. nearly deficiency). Blood 78: 3291–3297, 1991 10 yr ago (30). They demonstrated the efficacy of soluble 12. Yamashita M, Ueda E, Kinoshita T, Takami T, Ojima A, Ono H, complement 1 (sCR1) in a variety of glomerulone- Tanaka H, Kondo N, Orii T, Okada N, Okada H, Inoue K, Kitani phritis models in rats. Soluble Crry-IgG chimeric protein was T: Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal also effective in models of immunologic glomerular diseases hemoglobinuria. New Engl J Med 323: 1184–1189, 1990 (31). Although soluble DAF was effective in vitro, its efficacy 13. Shichishima T, Saitoh T, Terasawa T, Noji H, Kai T, Maruyama was marginal in vivo (32). While DAF-IgG chimera was less Y: Complement sensitivity of erythrocytes in a patient with effective in vitro, probably due to steric constraints, DAF-Ig inherited complete deficiency of CD59 or with the Inab pheno- had a much extended half-life in the circulation compared with type. Br J Haemat 104: 303–306, 1999 soluble DAF and was concomitantly more effective in vivo 14. Nomura A, Nishikawa K, Yuzawa Y, Okada H, Okada N, Mor- (33). Construction of chimeric complement regulatory proteins gan BP, Sara JP, Nadai M, Hasegawa T, Matsuo S: Tubuloin- with a longer half-life in vivo may open the door to novel terstitial injury induced in rats by a monoclonal antibody which therapeutic approaches. inhibits function of a membrane inhibitor of complement. J Clin Recombinant soluble CD59 has also been found more ef- Invest 96: 2348–2356, 1995 fective in vitro than in vivo. Recent studies demonstrated that 15. Matsuo S, Ichida S, Takizawa H, Okada N, Baranyi L, Iguchi A, Morgan BP, Okada H: In vivo effects of monoclonal antibodies fusion of CD59 with IgG or CR2 targets these complement which functionally inhibit complement regulatory proteins in inhibitors to sites of disease and improves their efficacy rats. J Exp Med 180: 1619–1627, 1994 (34,35). 16. Watanabe M, Morita Y, Mizuno M, Nishikawa K, Yuzawa Y, The potential of using complement regulators to modify Hotta N, Morgan BP, Okada N, Okada H, Matsuo S: CD59 renal disease exists not just for acute immune injury. Our protects rat kidney from complement mediated injury in collab- studies on C6-deficient rats demonstrated that amelioration of oration with Crry. Kidney Int 58: 1569–1579, 2000 J Am Soc Nephrol 14: 2411–2413, 2003 Complement Regulatory Proteins 2413

17. Nangaku M, Alpers CE, Pippin J, Shankland SJ, Kurokawa K, intravascular hemolysis and hemoglobinuria. Blood 98: 442– Adler S, Morgan BP, Johnson RJ, Couser WG: CD59 protects 449, 2001 glomerular endothelial cells from immune-mediated thrombotic 28. Acosta J, Hettinga J, Fluckiger R, Krumrei N, Goldfine A, microangiopathy in rats. J Am Soc Nephrol 9: 590–597, 1998 Angarita L, Halperin J: Molecular basis for a link between 18. Matsuo S, Nishikage H, Yoshida F, Nomura A, Piddlesden SJ, complement and the vascular complications of diabetes. Proc Morgan BP: Role of CD59 in experimental glomerulonephritis in Natl Acad Sci 97: 5450–5455, 2000 rats. Kidney Int 46: 191–200, 1994 29. Qin X, Krumrei N, Grubissich L, Dobarro M, Aktas H, Perez G, 19. Cunningham PN, Hack BK, Ren G, Minto AWM, Morgan BP, Halperin JA: Deficiency of the mouse complement regulatory Quigg RJ: Glomerular complement regulation is overwhelmed in protein mCd59b results in spontaneous hemolytic anemia with passive Heymann nephritis. Kidney Int 60: 900–909, 2001 activation and progressive male infertility. Immunity 18: 20. Hanafusa N, Sogabe H, Yamada K, Wada T, Fujita T, Nangaku 217–227, 2003 M: Contribution of genetically engineered animals to the analy- 30. Couser WG, Johnson RJ, Young BA, Yeh G, Toth CA, Rudolph ses of complement in the pathogenesis of nephritis. Nephrol Dial AR: The effects of soluble recombinant 1 Transplant 17[Suppl 9], 34–36, 2002 on complement-mediated experimental glomerulonephritis. JAm 21. Sogabe H, Nangaku M, Ishibashi Y, Wada T, Fujita T, Sun X, Soc Nephrol 5: 1888–1894, 1995 Miwa T, Madaio MP, Song W: Increased susceptibility of decay- 31. Bao L, Haas M, Kraus DM, Hack BK, Rakstang JK, Holers VM, accelerating factor (DAF) deficient mice to anti-GBM glomeru- Quigg RJ: Administration of a soluble recombinant complement lonephritis. J Immunol 167: 2791–2797, 2001 C3 inhibitor protects against renal disease in MRL/lpr mice. JAm 22. Lin F, Emancipator SN, Salant DJ, Medof ME: Decay-acceler- Soc Nephrol 14: 670–679, 2003 ating factor confers protection against complement-mediated 32. Sogabe R, Quigg RJ, Okada N, Miyata T, Inagi R, Kurokawa K, injury in acute nephrotoxic nephritis. Lab Invest 82: Fujita T, Nangaku M: Gene therapy for renal injury model rat 563–569, 2002 using an adenovirus vector encoding the soluble rat Crry gene. 23. Bao L, Haas M, Boackle SA, Kraus DM, Cunningham PN, Park Clin Exp Nephrol 6: 216–223, 2002 P, Alexander JJ, Anderson RK, Culhane K, Holers VM, Quigg 33. Harris CL, Williams AS, Linton SM, Morgan BP: Coupling RJ: Transgenic expression of a soluble complement inhibitor complement regulators to immunoglobulin domains generates protects against renal disease and promotes survival in MRL/lpr effective anti-complement reagents with extended half-life in mice. J Immunol 168: 3601–3607, 2002 vivo. Clin Exp Immunol 129: 198–207, 2002 24. Schiller B, Cunningham PN, Alexander JJ, Bao L, Holers VM, 34. Song H, He C, Knaak C, Guthridge JM, Holers VM, Tomlinson Quigg RJ: Expression of a soluble complement inhibitor protects S: -mediated targeting of complement transgenic mice from antibody-induced acute renal failure. JAm inhibitors to sites of complement activation. J Clin Invest 111: Soc Nephrol 12: 71–79, 2001 1875–1885, 2003 25. Quigg RJ, He C, Lim A, Berthiaume D, Alexander JJ, Kraus D, 35. Zhang HF, Yu J, Bajwa E, Morrison SL, Tomlinson S: Targeting Holers VM: Transgenic mice overexpressing the complement of functional antibody-CD59 fusion proteins to a cell surface. inhibitor Crry as a soluble protein are protected from antibody- J Clin Invest 103: 55–61, 1999 induced glomerular injury. J Exp Med. 188: 1321–1331, 1998 36. Nangaku M, Pippin J, Couser WG: C6 mediates chronic pro- 26. Miwa T, Zhou L, Hilliard B, Molina H, Song WC Crry, but not gression of tubulointerstitial damage in remnant kidney rats. CD59 and DAF, is indispensable for murine erythrocyte protec- J Am Soc Nephrol 13: 928–936, 2002 tion in vivo from spontaneous complement attack. Blood 99: 37. Nangaku M, Pippin J, Couser WG: Complement membrane 3707–3716, 2002 attack complex (C5b-9) mediates interstitial disease in experi- 27. Holt DS, Botto M, Bygrave AE, Hanna SM, Walport MJ, Mor- mental nephrotic syndrome. J Am Soc Nephrol 10: 2323–2331, gan BP: Targeted deletion of the CD59 gene causes spontaneous 1999

See related article, “CD59a Deficiency Exacerbates Accelerated Nephrotoxic Nephritis in Mice,” on pages 2271–2279.